Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
An update from Prestige Consumer Healthcare ( (PBH) ) is now available.
On February 5, 2026, Prestige Consumer Healthcare reported that third-quarter fiscal 2026 revenue for the period ended December 31, 2025 declined 2.4% year-on-year to $283.4 million, as constrained supply of its Clear Eyes products weighed on its Eye & Ear Care category, pulling down both North American and international OTC segment sales. Net income for the quarter fell to $46.7 million, or $0.97 per diluted share, while adjusted diluted EPS came in at $1.14, reflecting adjustments related to a supplier loan write-off and acquisition-related costs. For the first nine months of fiscal 2026, revenue dropped 4.1% to $807.1 million and diluted EPS slid to $2.78, though free cash flow strengthened to $208.8 million, supporting $155.6 million of share repurchases and leaving net debt at about $1.0 billion with leverage of 2.6x. The company closed its acquisition of eye care supplier Pillar5 Pharma in December and, while acknowledging a challenging consumer environment and ongoing Clear Eyes supply issues, narrowed its full-year fiscal 2026 outlook to approximately $1.1 billion in revenue and about $4.54 in adjusted diluted EPS, while reaffirming free cash flow guidance of at least $245 million, underscoring continued emphasis on cash generation, brand-building and disciplined capital allocation.
The most recent analyst rating on (PBH) stock is a Hold with a $66.00 price target. To see the full list of analyst forecasts on Prestige Consumer Healthcare stock, see the PBH Stock Forecast page.
Spark’s Take on PBH Stock
According to Spark, TipRanks’ AI Analyst, PBH is a Neutral.
Prestige Consumer Healthcare’s overall stock score is driven by its strong financial performance and reasonable valuation. However, the bearish technical indicators and challenges highlighted in the earnings call, such as declining revenue and supply constraints, weigh on the score. The company’s strategic focus on e-commerce growth and market share expansion in the dental category are positive factors that could support future performance.
To see Spark’s full report on PBH stock, click here.
More about Prestige Consumer Healthcare
Prestige Consumer Healthcare Inc., listed on the NYSE as PBH, operates in the over-the-counter (OTC) healthcare industry, marketing branded consumer healthcare products primarily in North America and internationally. Its portfolio includes eye and ear care, among other OTC categories, with a notable focus on the Clear Eyes brand, and it competes in both North American and international OTC healthcare markets.
Average Trading Volume: 418,495
Technical Sentiment Signal: Sell
Current Market Cap: $3.22B
See more data about PBH stock on TipRanks’ Stock Analysis page.